Name: COMPLETE / SUBSTANCE : 1,3-propanediol, 2-butyl-2-ethyl- / 115-84-4 Tue, 5 Sep 2023, 13:07:05+0900 /

Legal entity owner: National Institute of Health Sciences / Kawasaki / Japan

Printing date: 2023-09-05T13:07:05.977+09:00

Table of Contents

DOSSIER:

UUID: 0
Dossier UUID:
Author:
Date: 2023-09-05T13:07:05.667+09:00
Remarks:

Dossier header

Dossier submission type

Name
Complete table of contents

Version
core 8.0

Name (given by user)

Dossier subject

Dossier subject
1,3-propanediol, 2-butyl-2-ethyl- / 115-84-4

Public name

Submitting legal entity
National Institute of Health Sciences / Kawasaki / Japan

Dossier creation date/time
Tue, 5 Sep 2023, 13:07:05+0900

Used in category

LEGAL_ENTITY: National Institute of Health Sciences

UUID: IUC4-b036ff75-0f3c-323b-b200-ed5f46cf5101
Dossier UUID:
Author:
Date: 2022-11-07T15:49:29.000+09:00
Remarks:

General information

Legal entity name
National Institute of Health Sciences

Remarks
Disclaimer: The contents in this document were created based on the MHLW (Ministry of Health, Labour and Welfare) peer reviewed study reports (in Japanese) in JECDB (Japan Existing Chemical Database) at http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp. Authorship is in the Division of Risk Assessment, the National Institute of Health Sciences, and the contents do not reflect any o fficial MHLW opinions or any other regulatory policies.

Address

Address 1
Tonomachi 3-25-26

Address 2
Kawasaki-ku

Postal code
210-9501

Town
Kawasaki

Region / State
Kanagawa

Country
Japan
JP

Identifiers

Other IT system identifiers

IT system
LEO

ID
10767

IT system
IUCLID4

ID
16558402024DIV750

1,3-propanediol, 2-butyl-2-ethyl-

OECD

Health Effects

Repeated dose toxicity: oral

ENDPOINT_STUDY_RECORD: RepeatedDoseToxicityOral. 001

UUID: d34a71b8-fb94-44aa-a247-39c3bb3f82e8
Dossier UUID:
Author:
Date: 2022-03-25T14:28:02.000+09:00
Remarks:

Administrative data

Endpoint
short-term repeated dose toxicity: oral

Type of information
experimental study

Adequacy of study
key study

Robust study summary
false

Used for classification
false

Used for SDS
false

Reliability
1 (reliable without restriction)

Rationale for reliability incl. deficiencies
guideline study OECD Test Guideline study under GLP condition
Reliability 1

Cross-reference

Reason / purpose for cross-reference
reference to same study

Related information
OECD / Toxicity to reproduction / ToxicityReproduction. / 1,3-propanediol, 2-butyl-2-ethyl- / 115-84-4

Data source

Reference

Combined repeat dose and reproductive/developmental toxicity screening test of 1,3-propanediol, 2-bu / Ministry of Health, Labour and Welfare (MHLW), Japan / study report

Data access
data published https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4d.pdf

Materials and methods

Test guideline

Qualifier
according to guideline

Guideline
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

Deviations
no

GLP compliance
yes

Limit test
no

Test material

Test material information
1,3-propanediol, 2-butyl-2-ethyl-

Specific details on test material used for the study
- Name of test material (as cited in study report): 1,3-propanediol, 2-butyl-2-ethyl
- Analytical purity: 99.8%
- Storage condition of test material: Cold and dark place (2-8°C)
- Stability under test conditions: The stability of test material was identified by analysis of the re mainder.

Test animals

Species
rat
common rodent species

Strain
other: Crl: CD (SD)

Sex
male/female

Details on test animals or test system and environmental conditions
TEST ANIMALS
- Source: Charles River Japan, Inc., Atsugi Breeding Center.
- Age at study initiation: 10 weeks old
- Weight at study initiation: Male: 378 g (353-416 g), Female: 233 g (209-265 g)
- Housing: Animals were individually housed in bracket-type metallic wire-mesh cages (254W × 350D × 170H mm), from gestation day 17 to lactation day 4, Dams were bred individually or with individual littermates in plastic cages (340W x 400D x 185H mm) and bedding.
- Diet: Solid feed (NMF: Oriental Yeast Co., ltd.) was given ad libitum.
- Water: Tap water was given ad libitum.
- Acclimation period: 16 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23±3 (actual temperature: 22-24°C)
- Humidity (%): 50±20% (actual humidity: 40-60%)
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12 hr dark/12 hr light (light: 7:00-19:00)

Administration / exposure

Route of administration
oral: gavage

Vehicle
methylcellulose 0.5w/v%

Details on oral exposure
- Amount of vehicle (if gavage): 5 mL/kg
- Dosing volume: 5 mL/kg

Analytical verification of doses or concentrations
yes

Details on analytical verification of doses or concentrations
The concentration of test suspensions was analyzed by GC on the dosages used in groups of males at weeks 1 and 6 of administration. Results showed that the concentration of test suspensions in each concentration was 94.5 to 107.0% of the nominal concentration and both values were within the acceptable range (concentration: percentage of nominal concentration, 100±10%)

Duration of treatment / exposure
(P) Males: 42 days including 14 days pre-mating
(P)Females: 41-46 days including 14 days pre-mating, mating and gestation periods and the days until day 4 of lactation
Female (no mating, satellite group): 42 days

Frequency of treatment
Once/day, 7 days/week

Doses / concentrations

Dose / conc.	
20	mg/kg bw/day (actual dose received)
Dose / conc.	
100	mg/kg bw/day (actual dose received)
Dose / conc.	
500	mg/kg bw/day (actual dose received)

No. of animals per sex per dose
Mating group: 12 animals/sex/dose (0, 20, 100, and 500 mg/kg bw/day)
Non-mating group: 10 females/dose (0 and 500 mg/kg bw/day)
Recovery group: 5 males/dose in the mating group and 5 females/dose in the non-mating groups (0 and 500 mg/kg bw/day)

Control animals
yes, concurrent vehicle

Details on study design
- Dose selection rationale: Based on the results of a 14-day preliminary study, the highest dose of 500 mg/kg bw/day was selected as an expected obvious toxic dose, and the lowest dose of 20 mg/kg bw/day was selected as an expected no toxic dose. The middle dose levels of 100 mg/kg bw/day were selected.

[14-day preliminary study]
A 14-day repeated dose oral toxicity test (Crl:CD(SD) rats, doses: 0, 250, 500 or 1000 mg/kg bw/day). At 1,000 mg/kg bw/day, ataxia and prone/lateral position in males and females, increased platelet, decreased AST and glucose in males, increased liver weight in males and females, decreased thymus weight in males, increased kidney weight in females, elevated region of forestomach in males and females, large kidney in males were observed. At 500 mg/kg bw/day, ataxia in females, decreased thymus weight in males were observed. At 250 mg/kg bw/day, decreased thymus weight in males were observed.

- Rationale for animal assignment (if not random): Body weight-balanced randomization

Examinations

Observations and examinations performed and frequency
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: 4 times/day (before administration, immediately after administration, 30 minutes after administration and 1-3 hours after administration) during the administration period. Once a day during the recovery period.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:
Males in the main groups and females in the non-mating groups: once before the start of administration, once every weekly during the administration.
Females in the mating groups: once before the start of administration, days specified during mating, gestation, and lactation (mated animals: gestation days 1, 7, 14 and 20, unmated animals: 6 and 13 days after the start of mating, parturient animals: lactation day 4)
Males and females in the recovery groups: once before the start of administration, once every weekly during the administration and recovery periods.

BODY WEIGHT: Yes
- Time schedule for examinations:
Males in the main groups and females in the non-mating groups: days 1, 8, 15, 22, 29, 36 and 42 of administration and on the day of necropsy
Males and females in the recovery groups: days 1, 8, 15, 22, 29, 36 and 42 of administration, and days 1, 8 and 14 of recovery and on the day of necropsy.
Females in the mating groups: days 1, 8 and 15 of administration (uncopulated animals: day 22 of administration), days 0, 7, 14, and 20 of gestation, days 0, 4 of lactation, and on the day of necropsy

Food consumption: Yes
Measurement of food consumption was conducted on all animals at the following frequencies:
Males in the main groups and females in the non-mating groups: days 1, 8, 15, 30 and 42 of administration
Males and females in the recovery groups: days 1, 8, 15, 30 and 42 of administration, and days 1, 8 and 14 of recovery
Females in the mating groups: days 1, 8 and 15 of administration, days 0, 7, 14, and 20 of gestation, days 2 and 4 of lactation

OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes

- Time schedule for collection of blood: At the end of administration period, or at the end of recovery period in both sexes
- Anaesthetic used for blood collection: Isoflurane
- Animals fasted: Yes
- How many animals:
5 animals/sex/group
- Parameters examined: red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, reticulocyte percentage, platelet count, white blood cell count, differential white blood cell count, absolute number of each white blood cell, prothrombin time, activated partial thromboplastin time, fibrinogen.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of administration period, or at the end of recovery period in both sexes
- Animals fasted: Yes
- How many animals:
5 animals/sex/group
- Parameters checked: ALP, total cholesterol, triglyceride, phospholipids, total bilirubin, glucose, blood urea nitrogen, creatinine, sodium, potassium, chloride, calcium, inorganic phosphorus, total protein, albumin, A/G ratio, AST (GOT), ALT (GPT), LDH, γ-GTP

URINALYSIS OF MALES: Yes
- Time schedule for collection of urine: final week of administration (days 36 to 37 of administration) and in the final week of recovery (days 8 to 9 of recovery)
- Metabolism cages used for collection of urine: Yes
A urine collector to collect four-hour urine samples under fasting but ad libitum drinking conditions, followed by collection of 20-hour urine samples under ad libitum feeding and drinking conditions.
- How many animals: 5 animals/group
- Parameters checked: pH, protein, ketones, glucose, occult blood, bilirubin, urobilinogen, color, sediment, urine volume (4-hour volume), osmotic pressure, sodium, potassium, chloride, urine volume (20-hour volume), water intake (24-hour volume)

BLOOD HORMONE: No

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations:
Males in the main groups and females in the non-mating groups: final week of administration (day 38 of administration)
Females in the mating groups: lactation day 4 (day 41 to day 43 of administration) after necropsy of F1 pups
Males and females in the recovery groups: final week of administration (day 38 of administration) and in the final week of recovery (day 10 of recovery).
- Dose groups that were examined: All dose groups (5 animals/sex/group)
- Battery of functions tested:
1) Manipulative Test. Auditory response, approach response, touch response, tail pinch response, pupillary reflex, aerial righting reflex, landing foot splay
2) Measurement of Grip Strength. Following manipulative test, grip strength of forelimb and hind limb were measured by CPU gauge MODEL-RX-5 (AIKOH Engineering Co., Ltd.).
3) Measurement of Motor Activity. Following measurement of grip strength, motor activity was measured by a motor activity sensor for experimental animals NS-AS01 (Neuro Science, Inc.). The measurement was conducted for 1 hour, and measured values at 10-minute intervals and from 0 to 60 minutes were collected.

Sacrifice and pathology
GROSS PATHOLOGY: Yes
ORGAN WEIGHT: Yes [brain, pituitary, thyroids (including parathyroids), adrenal gland, thymus, spleen, heart, liver, kidney, testis, epididymis, prostate, seminal vesicles, ovary, uterus]

HISTOPATHOLOGY: Yes, [cerebrum, cerebellum (including pons), sciatic nerve, spinal cord (thoracic), eye ball, optic nerve, Harderian gland, pituitary, thyroid, parathyroid, adrenal glands, thymus, spleen, submandibular lymph nodes, mesenteric lymph nodes, heart, thoracic aorta, trachea, lung (including bronchial), tongue, larynx, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, submandibular gland, liver, pancreas, kidney, bladder, testis, ovary, epididymis, uterus, vagina, pro state, seminal vesicles, skin (inguinal), mammary gland (inguinal), sternum and femur (including bone marrows), skeletal muscle of femur, and individual identification site (pinna with ear tag)]

Statistics
For quantitative data, homogeneity of variance was tested using Bartlett method first. If the variance was homogenous, statistical difference between each treatment group and the control group was analyzed using Dunnett method. If not homogenous, statistical difference between each treatment group and the control group was tested using Steel method. For comparison of quantitative data be tween two groups in the recovery test, homogeneity of variance was analyzed by F-test. Then, if homo genous, student's t-test was applied. If not homogenous, Aspin-Welch's t-test was used.
Regarding clinical observation (except for frequency of urination, defecation, rearing and grooming) and sensory reactivity, Steel test was applied. Regarding auditory response, approach response, touch response, tail pinch response, pupillary reflex, aerial righting reflex, Fisher's test was applied.

Results and discussion

Results of examinations

Clinical signs
effects observed, treatment-related

Mortality
no mortality observed

Body weight and weight changes
no effects observed

Food consumption and compound intake (if feeding study)
no effects observed

Food efficiency
not examined

Water consumption and compound intake (if drinking water study)
not examined

Ophthalmological findings
not examined

Haematological findings
no effects observed

Clinical biochemistry findings
no effects observed

Urinalysis findings
effects observed, treatment-related

Behaviour (functional findings)
effects observed, treatment-related

Immunological findings
not examined

Organ weight findings including organ / body weight ratios
effects observed, treatment-related

Gross pathological findings
effects observed, treatment-related

Neuropathological findings
not examined

Histopathological findings: non-neoplastic
effects observed, treatment-related

Histopathological findings: neoplastic
not examined

Details on results
CLINICAL SIGNS AND MORTALITY:
Mortality: There was no death.
Clinical signs:
[At the dosing period]: Ataxia was observed in males and females at 500 mg/kg bw/day, and prone/ lateral position was observed in mating females at 500 mg/kg bw/day.
[At the recovery period]: There were no changes related to the test substance in any groups.

DETAILED CLINICAL OBSERVATIONS:
There were no changes related to the test substance in any groups at the dosing and recovery perio ds.

BODY WEIGHT:
There were no changes related to the test substance in any groups at the dosing and recovery periods.

FOOD CONSUMPTION:
There were no changes related to the test substance in any groups at the dosing and recovery period s.

URINALYSIS:
[At the dosing period]: A decrease tendency in urine pH was observed in males and non-mating females at 500 mg/kg bw/day.
[At the recovery period]: There were no changes related to the test substance in any groups.

HAEMATOLOGY:
[At the end of dosing period]: An increase in lymphocyte (%) and a decrease in neutrophil (%) were observed in males at 500 mg/kg bw/day and in mating females at 20 mg/kg bw/day and above. Thes e changes were considered of little toxicological significance because there were no abnormalities in related parameters such as white blood cell count.
[At the end of recovery period]: There were no changes related to the test substance in any groups.

CLINICAL CHEMISTRY:
[At the end of dosing period]: Decreases in glucose was observed in non-mating females at 500 mg/ kg bw/day. This change was considered of little toxicological significance because it was a minor change and there were no histopathological changes in the pituitary, thyroid, adrenal, or liver asso ciated with glycemic regulation.
[At the end of recovery period]: There were no changes related to the test substance in any groups.

NEUROBEHAVIOURAL EXAMINATION:
1) MANIPULATIVE TEST:
There were no changes related to the test substance in any groups at the dosing and recovery periods.
2) GRIP STRENGTH TEST:

There were no changes related to the test substance in any groups at the dosing and recovery per iods.
3) LOCOMOTOR ACTIVITY MEASUREMENT:
[At the dosing period]: A decrease in locomotor activity was observed in mating females at 500 mg/kg bw/day.
[At the recovery period]: There were no changes related to the test substance in any groups.

ORGAN WEIGHTS:
[At the end of dosing period]:
An increase in relative liver weight was observed in males and females at 500 mg/kg bw/day. An inc rease in relative kidney weight was observed in males at 100 mg/kg bw/day. Increases in absolute and relative kidney weights were observed in males at 500 mg/kg bw/day.
[At the end of recovery period]: An increase in relative liver weight was observed in non-mating fema les at 500 mg/kg bw/day.

GROSS PATHOLOGY:
[At the end of dosing period]:
Thickening in limiting ridge of stomach was observed in males at 500 mg/kg bw/day.
[At the end of recovery period]:
There were no changes related to the test substance in any groups.

HISTOPATHOLOGY: NON-NEOPLASTIC:
[At the end of dosing period]:
Kidney: Granular cast, regenerated tubule, eosinophilic body in tubular cell were observed in males at 100 mg/kg bw/day and above. Dilatated tubule, necrosis or desquamation in tubular cell were obs erved in males at 500 mg/kg bw/day.
Stomach: Hyperplasia of squamous in limiting ridge was observed in males and non-mating females at 500 mg/kg bw/day.
[At the end of recovery period]:
Kidney: Granular cast, regenerated tubule, eosinophilic body in tubular cell were observed in males at 500 mg/kg bw/day.

Effect levels

Key result
false

Dose descriptor
NOAEL

Effect level

20 mg/kg bw/day (actual dose received)

Based on
test mat.

Sex
male

Basis for effect level
histopathology: non-neoplastic
Kidney: Granular cast, regenerated tubule, eosinophilic body in tubular cell were observed in males at 100 mg/kg bw/day.
organ weights and organ / body weight ratios
An increase in relative kidney weight was observed in males at 100 mg/kg bw/day.

Key result
false

Dose descriptor
NOAEL

Effect level

100	mg/kg bw/day (actual dose received)

Based on
test mat.

Sex
female

Basis for effect level
behaviour (functional findings)
Decrease in locomotor activity was observed in mating females at 500 mg/kg bw/day.
clinical signs
Ataxia and prone/lateral position were observed in females at 500 mg/kg bw/day.
histopathology: non-neoplastic
Stomach: Hyperplasia of squamous in limiting ridge was observed in non-mating females at 500 mg/kg bw/day.
organ weights and organ / body weight ratios
An increase in relative liver weight was observed in females at 500 mg/kg bw/day.
urinalysis
A decrease tendency in urine pH was observed in non-mating females at 500 mg/kg bw/day.

Any other information on results incl. tables

Figures and Tables (in English) are available in the following full report of the study.

https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4d.pdf

Applicant's summary and conclusion

Conclusions
The NOAEL for repeated dose toxicity in this study was determined to be 20 and 100 mg/kg bw/day for males and females, respectively.

Executive summary

In the combined repeated dose and reproductive/developmental screening test (OECD TG422), SD rats were treated orally with 1,3-propanediol, 2-butyl-2-ethyl at the doses of 0, 20, 100 and 500 mg/kg bw/day. Males (12 males/dose: 5 males were treated as a recovery group) were dosed for 42 days including a 14 day pre-mating period and mating periods. Mating females (12 females/dose) were dosed for 41-46 days including 14 day premating, mating, and gestation periods and days until day 4 of lactation. Non-mating female (10 females/dose: 5 females were treated as a recovery group) were dosed for 42 days.

The following findings were observed in examination at the administration period or end of administration period. In the clinical signs, ataxia was observed in males and females at 500 mg/kg bw/day, and prone/lateral position was observed in mating females at 500 mg/kg bw/day. In the locomotor activity measurement, decrease in locomotor activity was observed in mating females at 500 mg/kg bw/day. In the urinalysis, decrease tendency in urine pH was observed in males and non-mating females

at 500 mg/kg bw/day. In the organ weights, an increase in relative liver weight was observed in males and females at 500 mg/kg bw/day. An increase in relative kidney weight was observed in males at 100 mg/kg bw/day. Increases in absolute and relative kidney weights were observed in males at 500 mg/kg bw/day. In the gross pathology, thickening in limiting ridge of the stomach was observed in males at 500 mg/kg bw/day. In the histopathology, granular cast, regenerated tubule and eosinophilic body in tubular cell of kidney in males at 100 mg/kg bw/day and above, dilatated tubule, necrosis or desquamation in tubular cell of kidney in males at 500 mg/kg bw/day, hyperplasia of squamous in limiting ridge of the stomach in males and non-mating females at 500 mg/kg bw/day were observed. Based on the above results, NOAEL for the repeated dose toxicity of 1,3-propanediol, 2-butyl-2-ethyl was determined to be 20 and 100 mg/kg bw/day for males and female rats, respectively.

Genetic toxicity in vitro

ENDPOINT_STUDY_RECORD: Genetic toxicity in vitro.001

UUID:	3f4e2678-9bb9-4de6-b363-985bb60a6c8c
Dossier UUID:	
Author:	
Date:	2022-03-25T10:46:38.000+09:00
Remarks:	

Administrative data

Endpoint
in vitro gene mutation study in bacteria

Type of information
experimental study

Adequacy of study
key study

Robust study summary
false

Used for classification
false

Used for SDS
false

Reliability
1 (reliable without restriction)

Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source

Reference

Reverse Mutation Test of 1,3-Propanediol, 2-butyl-2-ethyl on Bacteria. / Ministry of Health, Labour and Welfare (MHLW), Japan / study report

Data access
data published

Materials and methods

Test guideline

Qualifier
according to guideline

Guideline
OECD Guideline 471 (Bacterial Reverse Mutation Assay)

in vitro gene mutation study in bacteria

Deviations
no

Qualifier
according to guideline

Guideline
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
genetic toxicity in vitro, other

Deviations
no

GLP compliance
yes

Type of assay
bacterial reverse mutation assay
in vitro gene mutation study in bacteria

Test material

Test material information
1,3-propanediol, 2-butyl-2-ethyl-

Specific details on test material used for the study
- Name of test material (as cited in study report): 1,3-Propanediol, 2-butyl-2-ethyl
- Analytical purity: 99.8%

Method

Species / strain

Species / strain / cell type
S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
bacteria

Species / strain / cell type
E. coli WP2 uvr A
bacteria

Metabolic activation
with and without

Metabolic activation system
S9 mix; SD male rat liver, induced by phenobarbital and 5,6-benzoflavone

Justification for deviation from the high dose level
-S9 mix:
39.1, 78.1, 156, 313, 625, 1250 µg/plate (TA100 strain)
9.77, 19.5, 39.1, 78.1, 156, 313 µg/plate (TA1535, TA1537 strains)
156, 313, 625, 1250, 2500, 5000 µg/plate (WP2uvrA, TA98 strains)
+S9 mix:

39.1, 78.1, 156, 313, 625, 1250 µg/plate (TA100, TA1535, TA1537 strains)
156, 313, 625, 1250, 2500, 5000 µg/plate (WP2uvrA, TA98 strains)

Maximum concentration was established based on the result of the preliminary test at concentration up to 5000 ug/plate. In this test, the growth inhibition was observed at 313 µg/plate and above for S. typhimurium TA 1535 and TA1537 strains without S9 mix, at 1250 µg/plate and above for S. typhimurium TA100 strain with or without S9 mix, for S. typhimurium TA1535 and TA1537 stains with S9 mix, at 5000 µg/plate for S. typhimurium TA98 and E. coli WP2uvrA with or without S9 mix.

Vehicle / solvent
- Vehicle(s)/solvent(s) used: DMSO

Controls

Untreated negative controls
no

Negative solvent / vehicle controls
yes

True negative controls
no

Positive controls
yes

Positive control substance
other: -S9 mix: 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide (AF-2), sodium azide (SAZ) and 2-methoxy-6-chloro-9-[3-(2-chloroethyl)-aminopropylamino]acridine 2HCl (ICR-191) ;
+S9 mix: 2-aminoanthracene (2AA), benzo[a]pyrene (B[a]P)

Details on test system and experimental conditions
METHOD OF APPLICATION: Preincubation
DURATION- Preincubation period: 20 min at 37°C
- Exposure duration:48 or 50 hrs
NUMBER OF PLATES: 3
NUMBER OF REPLICATIONS: 2
DETERMINATION OF CYTOTOXICITY
- Method: other: growth inhibition

Evaluation criteria
A chemical was judged to be mutagenic when the mean number of revertant colonies per plate increased more than twice that of the negative control and when the dose-related and reproducible i ncrease was observed.

Statistics
no

Results and discussion

Test results

Key result
true

Species / strain
S. typhimurium TA 1535

bacteria

Metabolic activation
with and without

Genotoxicity
negative

Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 313 µg/plate;
+S9 mix: 625 µg/plate and above

Vehicle controls validity
valid

Positive controls validity
valid

Key result
true

Species / strain
S. typhimurium TA 1537
bacteria

Metabolic activation
with and without

Genotoxicity
negative

Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 313 µg/plate;
+S9 mix: 1250 µg/plate

Vehicle controls validity
valid

Positive controls validity
valid

Key result
true

Species / strain
S. typhimurium TA 98
bacteria

Metabolic activation
with and without

Genotoxicity
negative

Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 2500 µg/plate and above;
+S9 mix: 2500 µg/plate and above

Vehicle controls validity
valid

Positive controls validity
valid

Key result
true

Species / strain
S. typhimurium TA 100
bacteria

Metabolic activation
with and without

Genotoxicity
negative

Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 1250 µg/plate;
+S9 mix: 1250 µg/plate

Vehicle controls validity
valid

Positive controls validity
valid

Key result
true

Species / strain
E. coli WP2 uvr A
bacteria

Metabolic activation
with and without

Genotoxicity
negative

Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 2500 µg/plate and above;
+S9 mix: 2500 µg/plate and above

Vehicle controls validity
valid

Untreated negative controls validity
not examined

Positive controls validity
valid

Any other information on results incl. tables

Figures and Tables (in Japanese) are available in the following full report of the study.

https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4e.pdf

Please also see the attached files (Tables in English)

Applicant's summary and conclusion

Conclusions
Interpretation of results (migrated information): negative

In a bacterial reverse mutation assay using Salmonella typhimurium TA100, TA1535, TA98, and TA 1537, and Escherichia coli WP2uvrA (OECD TG 471), 1,3-propanediol, 2-butyl-2-ethyl was negative with or without metabolic activation.

ENDPOINT_STUDY_RECORD: Genetic toxicity in vitro.002

UUID: 54d54bfa-7d24-4257-869d-9e2a9a092627
Dossier UUID:
Author:
Date: 2022-03-25T10:47:51.000+09:00
Remarks:

Administrative data

Endpoint
in vitro chromosome aberration study in mammalian cells

Type of information
experimental study

Adequacy of study
key study

Robust study summary
false

Used for classification
false

Used for SDS
false

Reliability
1 (reliable without restriction)

Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source

Reference

In Vitro Chromosomal Aberration Test of 1,3-Propanediol, 2-butyl-2-ethyl on Cultured Chinese Hamster / Ministry of Health, Labour and Welfare (MHLW), Japan / study report

Data access
data published

Materials and methods

Test guideline

Qualifier
according to guideline

Guideline
OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
in vitro cytogenicity / chromosome aberration study in mammalian cells

Deviations
no

Qualifier
according to guideline

Guideline
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
genetic toxicity in vitro, other

Deviations
no

GLP compliance
yes

Type of assay
other: in vitro mammalian chromosome aberration test

Test material

Test material information
1,3-propanediol, 2-butyl-2-ethyl-

Specific details on test material used for the study
- Name of test material (as cited in study report): 1,3-Propanediol, 2-butyl-2-ethyl
- Analytical purity: 99.8%

Method

Species / strain

Species / strain / cell type
other: Chinese hamster lung(CHL/IU) cells

Metabolic activation
with and without

Metabolic activation system
S9 mix; SD male rat liver, induced by phenobarbital and 5,6-benzoflavone

Justification for deviation from the high dose level
Cell growth inhibition study
-S9 mix (short-term treatment): 3.22, 6.45, 12.9, 25.8, 51.6, 103, 206, 413, 825, 1650 ug/mL
+S9 mix (short-term treatment): 3.22, 6.45, 12.9, 25.8, 51.6, 103, 206, 413, 825, 1650 ug/mL
-S9 mix (continuous treatment, 24hr): 3.22, 6.45, 12.9, 25.8, 51.6, 103, 206, 413, 825, 1650 ug/mL
-S9 mix (continuous treatment, 48hr): 3.22, 6.45, 12.9, 25.8, 51.6, 103, 206, 413, 825, 1650 ug/mL

Main study
-S9 (short-term treatment): 386, 463, 556, 667, 800 ug/mL
+S9 (short-term treatment): 386, 463, 556, 667, 800 ug/mL
-S9 (continuous treatment, 24hr): 98.8, 148, 222, 333, 500 ug/mL
-S9 (continuous treatment, 48hr): 98.8, 148, 222, 333, 500 ug/mL

Vehicle / solvent
- Vehicle(s)/solvent(s) used: DMSO

Controls

Untreated negative controls
no

Negative solvent / vehicle controls
yes

True negative controls
no

Positive controls
yes

Positive control substance
other: [-S9]: mitomycin C; [+S9]: cyclophosphamide

Details on test system and experimental conditions
METHOD OF APPLICATION:
Exposure duration:
- [short-term treatment]: 6 hrs + 18 hrs
- [continuous treatment]: 24, 48 hrs
SPINDLE INHIBITOR: Colcemid
STAIN: Giemsa stain (2 v/v%) for 15 min.
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: 100 + 100 cells /concentration
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth

Evaluation criteria
For the evaluation of the frequencies of structural aberrations and of polyploidy induced, the following criteria were employed. Appearance incidence of cell with chromosomal aberrations: Negative (-): less than 5%, Equivocal(±): more than 5% and less than 10%, Positive(+): 10% and above

Statistics
no

Results and discussion

Test results

Key result
true

Species / strain
other: Chinese hamster lung (CHL/IU) cells

Metabolic activation
with and without

Genotoxicity
negative

Cytotoxicity / choice of top concentrations
cytotoxicity

Vehicle controls validity
valid

Positive controls validity
valid

Additional information on results
RANGE-FINDING/SCREENING STUDIES (if applicable):

50% cell growth inhibition (IC50): 719 ug/mL (short-term treatment, +S9 mix), 732 ug/mL (short-term t reatment, -S9 mix), 340 ug/mL (continuous treatment, 24hr), 332 ug/mL (continuous treatment, 48hr)

Any other information on results incl. tables

Figures and Tables (in English) are available in the following full report of the study.

https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4f.pdf

Applicant's summary and conclusion

Conclusions
Interpretation of results (migrated information): negative with or without metabolic activation

In an in vitro chromosomal aberration test using CHL/IU cells (OECD TG 473), 1,3-propanediol, 2-butyl-2-ethyl was negative with or without metabolic activation.

Toxicity to reproduction

ENDPOINT_STUDY_RECORD: ToxicityReproduction.

UUID:	11f098b8-901d-40b9-b056-78658d53a2bb
Dossier UUID:	
Author:	
Date:	2022-03-25T14:28:55.000+09:00
Remarks:	

Administrative data

Endpoint
reproductive toxicity, other A combined repeated dose/reproductive developmental toxicity study

Type of information
experimental study

Adequacy of study
key study

Robust study summary
false

Used for classification
false

Used for SDS
false

Reliability
1 (reliable without restriction)

Rationale for reliability incl. deficiencies
guideline study OECD Test Guideline study under GLP condition
Reliability 1

Cross-reference

Reason / purpose for cross-reference
reference to same study

Related information
OECD / Repeated dose toxicity: oral / RepeatedDoseToxicityOral. 001 / 1,3-propanediol, 2-butyl-2-ethyl- / 115-84-4

Data source

Reference

Combined repeat dose and reproductive/developmental toxicity screening test of 1,3-propanediol, 2-bu / Ministry of Health, Labour and Welfare (MHLW), Japan / study report

Data access
data published https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4d.pdf

Materials and methods

Test guideline

Qualifier
according to guideline

Guideline
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

Deviations
no

GLP compliance
yes

Limit test
no

Test material

Test material information
1,3-propanediol, 2-butyl-2-ethyl-

Specific details on test material used for the study
- Name of test material (as cited in study report): 1,3-propanediol, 2-butyl-2-ethyl
- Analytical purity: 99.8%
- Storage condition of test material: Cold and dark place (2-8°C)
- Stability under test conditions: The stability of test material was identified by analysis of the re mainder.

Test animals

Species
rat

Strain
other: Crl: CD (SD)

Sex
male/female

Details on test animals or test system and environmental conditions

TEST ANIMALS
- Source: Charles River Japan, Inc., Atsugi Breeding Center.
- Age at study initiation: 10 weeks old
- Weight at study initiation: Male: 378 g (353-416 g), Female: 233 g (209-265 g)
- Housing: Animals were individually housed in bracket-type metallic wire-mesh cages (254W × 350D × 170H mm), from gestation day 17 to lactation day 4, Dams were bred individually or with individual littermates in plastic cages (340W x 400D x 185H mm) and bedding.

- Diet: Solid feed (NMF: Oriental Yeast Co., ltd.) was given ad libitum.
- Water: Tap water was given ad libitum.
- Acclimation period: 16 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23±3 (actual temperature: 22-24°C)
- Humidity (%): 50±20% (actual humidity: 40-60%)
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12 hr dark/12 hr light (light: 7:00-19:00)

Administration / exposure

Route of administration
oral: gavage

Vehicle
other: 0.5w/v% methylcellulose

Details on exposure
- Amount of vehicle (if gavage): 5 mL/kg
- Dosing volume: 5 mL/kg

Details on mating procedure
- M/F ratio per cage:1/1
- Length of cohabitation: up to 5 days
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy

Analytical verification of doses or concentrations
yes

Details on analytical verification of doses or concentrations
The concentration of test suspensions was analyzed by GC on the dosages used in groups of males at weeks 1 and 6 of administration. Results showed that the concentration of test suspensions in each concentration was 94.5 to 107.0% of the nominal concentration and both values were within the acceptable range (concentration: percentage of nominal concentration, 100±10%)

Duration of treatment / exposure

(P) Males: 42 days including 14 days pre-mating
(P)Females: 41-46 days including 14 days pre-mating, mating and gestation periods and the days until day 4 of lactation
Female (no mating, satellite group): 42 days

Frequency of treatment
Once/day, 7 days/week

Doses / concentrations

Dose / conc.	
0	mg/kg bw/day (actual dose received)
Dose / conc.	
20	mg/kg bw/day (actual dose received)
Dose / conc.	
100	mg/kg bw/day (actual dose received)
Dose / conc.	
500	mg/kg bw/day (actual dose received)

No. of animals per sex per dose
Mating group: 12 animals/sex/dose (0, 20, 100, and 500 mg/kg bw/day)
Non-mating group: 10 females/dose (0 and 500 mg/kg bw/day)

Recovery group: 5 males/dose in the mating group and 5 females/dose in the non-mating groups (0 and 500 mg/kg bw/day)

Control animals
yes, concurrent vehicle

Details on study design
- Dose selection rationale: Based on the results of a 14-day preliminary study, the highest dose of 500 mg/kg bw/day was selected as an expected obvious toxic dose, and the lowest dose of 20 mg/kg bw/day was selected as an expected no toxic dose. The middle dose levels of 100 mg/kg bw/day were selected.

[14-day preliminary study]
A 14-day repeated dose oral toxicity test (Crl:CD(SD) rats, doses: 0, 250, 500 or 1000 mg/kg bw/day). At 1,000 mg/kg bw/day, ataxia and prone/lateral position in males and females, increased platelet, decreased AST and glucose in males, increased liver weight in males and females, decreased thymus weight in males, increased kidney weight in females, elevated region of forestomach in males and females, large kidney in males were observed. At 500 mg/kg bw/day, ataxia in females, decreased thymus weight in males were observed. At 250 mg/kg bw/day, decreased thymus weight in males were observed.

- Rationale for animal assignment (if not random): Body weight-balanced randomization

Examinations

Parental animals: Observations and examinations

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: 4 times/day (before administration, immediately after administration, 30 minutes after administration and 1-3 hours after administration) during the administration period. Once a day during the recovery period.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:
Males in the main groups and females in the non-mating groups: once before the start of administration, once every weekly during the administration.
Females in the mating groups: once before the start of administration, days specified during mating, gestation, and lactation (mated animals: gestation days 1, 7, 14 and 20, unmated animals: 6 and 13 days after the start of mating, parturient animals: lactation day 4)
Males and females in the recovery groups: once before the start of administration, once every weekly during the administration and recovery periods.

BODY WEIGHT: Yes
- Time schedule for examinations:
Males in the main groups and females in the non-mating groups: days 1, 8, 15, 22, 29, 36 and 42 of administration and on the day of necropsy
Males and females in the recovery groups: days 1, 8, 15, 22, 29, 36 and 42 of administration, and days 1, 8 and 14 of recovery and on the day of necropsy.
Females in the mating groups: days 1, 8 and 15 of administration (uncopulated animals: day 22 of administration), days 0, 7, 14, and 20 of gestation, days 0, 4 of lactation, and on the day of necropsy

Food consumption: Yes
Measurement of food consumption was conducted on all animals at the following frequencies:
Males in the main groups and females in the non-mating groups: days 1, 8, 15, 30 and 42 of administration
Males and females in the recovery groups: days 1, 8, 15, 30 and 42 of administration, and days 1, 8 and 14 of recovery
Females in the mating groups: days 1, 8 and 15 of administration, days 0, 7, 14, and 20 of gestation, days 2 and 4 of lactation

OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of administration period, or at the end of recovery period in both sexes
- Anaesthetic used for blood collection: Isoflurane
- Animals fasted: Yes
- How many animals:
5 animals/sex/group
- Parameters examined: red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, reticulocyte percentage, platelet count, white blood cell count, differential white blood cell count, absolute number of each white blood cell, prothrombin time, activated partial thromboplastin time, fibrinogen.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of administration period, or at the end of recovery period in both sexes
- Animals fasted: Yes
- How many animals:
5 animals/sex/group
- Parameters checked: ALP, total cholesterol, triglyceride, phospholipids, total bilirubin, glucose, blood urea nitrogen, creatinine, sodium, potassium, chloride, calcium, inorganic phosphorus, total protein, albumin, A/G ratio, AST (GOT), ALT (GPT), LDH, γ-GTP

URINALYSIS OF MALES: Yes
- Time schedule for collection of urine: final week of administration (days 36 to 37 of administration) and in the final week of recovery (days 8 to 9 of recovery)
- Metabolism cages used for collection of urine: Yes
A urine collector to collect four-hour urine samples under fasting but ad libitum drinking conditions, followed by collection of 20-hour urine samples under ad libitum feeding and drinking conditions.
- How many animals: 5 animals/group
- Parameters checked: pH, protein, ketones, glucose, occult blood, bilirubin, urobilinogen, color, sediment, urine volume (4-hour volume), osmotic pressure, sodium, potassium, chloride, urine volume (20-hour volume), water intake (24-hour volume)

BLOOD HORMONE: No

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations:
Males in the main groups and females in the non-mating groups: final week of administration (day 38 of administration)
Females in the mating groups: lactation day 4 (day 41 to day 43 of administration) after necropsy of F1 pups
Males and females in the recovery groups: final week of administration (day 38 of administration) and in the final week of recovery (day 10 of recovery).
- Dose groups that were examined: All dose groups (5 animals/sex/group)
- Battery of functions tested:
1) Manipulative Test. Auditory response, approach response, touch response, tail pinch response, pupillary reflex, aerial righting reflex, landing foot splay
2) Measurement of Grip Strength. Following manipulative test, grip strength of forelimb and hind limb were measured by CPU gauge MODEL-RX-5 (AIKOH Engineering Co., Ltd.).
3) Measurement of Motor Activity. Following measurement of grip strength, motor activity was measured by a motor activity sensor for experimental animals NS-AS01 (Neuro Science, Inc.). The measurement was conducted for 1 hour, and measured values at 10-minute intervals and from 0 to 60 minutes were collected.

Oestrous cyclicity (parental animals)
Vaginal smears were collected from all females in the mating groups and microscopically examined every day from the day after the start of administration until the day copulation was confirmed. During the pre-mating administration period, vaginal smear pictures were classified as proestrus, estrus, metestrus or diestrus and examined for the frequency of estrus and interval between estruses (estrous cycle). During the mating period, vaginal smears were examined for the presence of sperm.

Sperm parameters (parental animals)
Parameters examined in all P male parental generations: testis weight, epididymis weight, histopatho logical examinations for testes, epididymides, seminal vesicle and ventral prostate.

Litter observations
PARAMETERS EXAMINED: The following parameters were examined in F1 offspring: Number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, and weight gain.
GROSS EXAMINATION OF DEAD PUPS: Yes, for external and internal abnormalities.

Postmortem examinations (parental animals)
METHOD OF SACRIFICED: All animals were sacrificed by exsanguination under isoflurane anesthesia.
SACRIFICE: Males in main groups and females in non-mating groups: On next day after the last administration (Day 43), Maternal animals: on Day 4 of lactation, and Male and females recovery anim als: on Day 14 of recovery.

ORGAN WEIGHT: Yes [brain, pituitary, thyroids (including parathyroids), adrenal gland, thymus, spleen, heart, liver, kidney, testis, epididymis, prostate, seminal vesicles, ovary, uterus]
HISTOPATHOLOGY: Yes, [cerebrum, cerebellum (including pons), sciatic nerve, spinal cord (thoracic), eye ball, optic nerve, Harderian gland, pituitary, thyroid, parathyroid, adrenal glands, thymus, spleen, submandibular lymph nodes, mesenteric lymph nodes, heart, thoracic aorta, trachea, lung (including bronchial), tongue, larynx, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, submandibular gland, liver, pancreas, kidney, bladder, testis, ovary, epididymis, uterus, vagina, prost ate, seminal vesicles, skin (inguinal), mammary gland (inguinal), sternum and femur (including bone marrows), skeletal muscle of femur, and individual identification site (pinna with ear tag)]

Postmortem examinations (offspring)
SACRIFICE
- The F1 offsprings were euthanized on PND4 by exsanguination under isoflurane anesthesia.
GROSS NECROPSY：Yes
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.
HISTOPATHOLOGY / ORGAN WEIGTHS
- Not examined.

Statistics
For quantitative data, homogeneity of variance was tested using Bartlett method first. If the variance was homogenous, statistical difference between each treatment group and the control group was analyzed using Dunnett method. If not homogenous, statistical difference between each treatment group and the control group was tested using Steel method. For comparison of quantitative data be tween two groups in the recovery test, homogeneity of variance was analyzed by F-test. Then, if homo genous, student's t-test was applied. If not homogenous, Aspin-Welch's t-test was used.
Regarding clinical observation (except for frequency of urination, defecation, rearing and grooming) and sensory reactivity, Steel test was applied. Regarding implantation index, stillborn index, live birth index, viability index and external abnormalities, Steel test was applied. Regarding copulation index, insemination index, fertility index, and delivery index, auditory response, approach response, touch response, tail pinch response, pupillary reflex, aerial righting reflex, Fisher's test was applied.

Reproductive indices
Each parameter was determined by the following equations:

Copulation index (%) = (No. of copulated animals / No. of mated animals) × 100
Fertility index (%) = (No. of pregnant females / No. of copulated females) × 100
Insemination index (%) = (No. of males which impregnated females / No. of copulated males) × 100
Gestation length (days) = No. of days from pregnancy day 0 to parturition day
Delivery index (%) = (No. of females which delivered liveborns / No. of pregnant females) × 100
Implantation index (%) = (No. of implantation sites / No. of corpora lutea) × 100
Stillborn index (%) = (No. of stillborn / No of liveborns and stillborns) × 100
Live birth index (%) = (No. of liveborn / No. of implantation sites) × 100
External abnormalities (%) = (No. of pups with external abnormalities / No. of liveborns) × 100
Sex ratio = No. of liveborns males / No. of liveborns
Sex ratio of live pups on day 4= No. of live males on day 4/ No. of live pups on day 4

Offspring viability indices
Viability index on postnatal day 4 (%) = (No. of live pups on day 4 / No. of liveborns on day 0) × 100

Results and discussion

Results: P0 (first parental generation)

General toxicity (P0)

Clinical signs
effects observed, treatment-related

Description (incidence and severity)
See 7.5.1 Repeated dose toxicity.001

Mortality
no mortality observed

Body weight and weight changes
no effects observed

Food consumption and compound intake (if feeding study)
no effects observed

Food efficiency
not examined

Water consumption and compound intake (if drinking water study)
not examined

Ophthalmological findings
not examined

Haematological findings
no effects observed

Clinical biochemistry findings
no effects observed

Urinalysis findings
effects observed, treatment-related

Description (incidence and severity)
See 7.5.1 Repeated dose toxicity.001

Behaviour (functional findings)
no effects observed

Immunological findings
not examined

Organ weight findings including organ / body weight ratios
effects observed, treatment-related

Description (incidence and severity)
See 7.5.1 Repeated dose toxicity.001

Gross pathological findings
effects observed, treatment-related

Description (incidence and severity)
See 7.5.1 Repeated dose toxicity.001

Neuropathological findings
not examined

Histopathological findings: non-neoplastic
effects observed, treatment-related

Description (incidence and severity)
See 7.5.1 Repeated dose toxicity.001

Histopathological findings: neoplastic
not examined

Reproductive function / performance (P0)

Reproductive function: oestrous cycle
no effects observed

Reproductive function: sperm measures
no effects observed

Reproductive performance
no effects observed

Details on results (P0)

General toxicity: See 7.5.1 Repeated dose toxicity.001
Reproductive function / performance: no effects observed

Effect levels (P0)

Key result
false

Dose descriptor
NOAEL

Effect level

20	mg/kg bw/day (actual dose received)

Based on
test mat.

Sex
male

Basis for effect level
organ weights and organ / body weight ratios
An increase in relative kidney weight was observed in males at 100 mg/kg bw/day.
histopathology: non-neoplastic
Kidney: Granular cast, regenerated tubule, eosinophilic body in tubular cell were observed in males at 100 mg/kg bw/day.

Key result
false

Dose descriptor
NOAEL

Effect level

100 mg/kg bw/day (actual dose received)

Based on
test mat.

Sex
female

Basis for effect level
clinical signs
Ataxia and prone/lateral position were observed in females at 500 mg/kg bw/day.
urinalysis
A decrease tendency in urine pH was observed in non-mating females at 500 mg/kg bw/day.
organ weights and organ / body weight ratios
An increase in relative liver weight was observed in females at 500 mg/kg bw/day.
histopathology: non-neoplastic
Stomach: Hyperplasia of squamous in limiting ridge was observed in non-mating females at 500 mg/kg bw/day.
other: NEUROBEHAVIOURAL EXAMINATION:
A decrease in locomotor activity was observed in mating females at 500 mg/kg bw/day.

Key result
false

Dose descriptor
NOAEL

Effect level

500 mg/kg bw/day (actual dose received)

Based on
test mat.

Sex
male/female

Basis for effect level
reproductive performance
No reproductive effects were observed in both males and females up to 500 mg/kg bw/day.

Results: F1 generation

General toxicity (F1)

Clinical signs
no effects observed

Mortality / viability
no mortality observed

Body weight and weight changes
no effects observed

Gross pathological findings
no effects observed

Details on results (F1)

No effects observed.

Effect levels (F1)

Key result
false

Dose descriptor
NOAEL

Generation
F1

Effect level

500 mg/kg bw/day (actual dose received)

Based on
test mat.

Sex
male/female

Basis for effect level
other:
There were no effects on developmental parameters up to 500 mg/kg bw/day.

Overall reproductive toxicity

Key result
false

Reproductive effects observed
no

Any other information on results incl. tables

Figures and Tables (in English) are available in the following full report of the study.

https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4d.pdf

Applicant's summary and conclusion

Conclusions
In the combined repeated oral dose toxicity study with the reproduction/developmental toxicity screening test (OECD TG 422) described above, there were no effects on the reproductive and developmental parameters up to 500 mg/kg bw/day. The NOAEL for the rat reproductive/developmental toxicity of 1,3-propanediol, 2-butyl-2-ethyl was regarded as 500 mg/kg bw/day, the highest dose tested.

DOMAIN

SUBSTANCE: 1,3-propanediol, 2-butyl-2-ethyl-

UUID:	bcf517d6-06ec-49a8-9a07-a591bb369cd8
Dossier UUID:	
Author:	
Date:	2023-09-05T13:06:53.767+09:00
Remarks:	

Substance name
1,3-propanediol, 2-butyl-2-ethyl-

Legal entity
National Institute of Health Sciences / Kawasaki / Japan

Identification of substance

Reference substance
1,3-propanediol, 2-butyl-2-ethyl- / 115-84-4

EC number	EC name
CAS number	**CAS name**
115-84-4	

IUPAC name

Role in the supply chain

Manufacturer
false

Importer
false

Only representative
false

Downstream user
false

References

Reference Substances

REFERENCE_SUBSTANCE: 1,3-propanediol, 2-butyl-2-ethyl-

UUID: 012d25fb-6126-44d7-964d-c433319ef9c9
Dossier UUID:
Author:
Date: 2022-03-25T14:24:38.000+09:00
Remarks:

Reference substance name
1,3-propanediol, 2-butyl-2-ethyl-

Inventory

CAS number
115-84-4

Molecular and structural information

Molecular formula
C9H20O2

Molecular weight

160.25

Test Materials

TEST_MATERIAL_INFORMATION: 1,3-propanediol, 2-butyl-2-ethyl-

UUID:	89431b8c-07f6-4817-a83d-735088fd2923
Dossier UUID:	
Author:	
Date:	2022-03-25T14:27:19.000+09:00
Remarks:	

Name
1,3-propanediol, 2-butyl-2-ethyl-

Literatures

LITERATURE: Combined repeat dose and reproductive/ developmental toxicity screening test of 1,3-propanediol, 2-butyl-2-ethyl by oral administration in rats

UUID: 98144ba0-8cd8-4a07-b339-6be5e102b4b0
Dossier UUID:
Author:
Date: 2021-10-22T15:37:28.000+09:00
Remarks:

General information

Reference Type
study report

Title
Combined repeat dose and reproductive/developmental toxicity screening test of 1,3-propanediol, 2-butyl-2-ethyl by oral administration in rats

Author
Ministry of Health, Labour and Welfare (MHLW), Japan

Year
2013

Bibliographic source
available in the web of Japan Existing Chemical Data Base (JECDB) at https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4d.pdf

Testing facility
BoZo Research Center

Report number
R-1088

LITERATURE: In Vitro Chromosomal Aberration Test of 1,3-Propanediol, 2-butyl-2-ethyl on Cultured Chinese Hamster Cells.

UUID: 6182aba2-60ae-481c-a1b0-c18f9b4deb1b
Dossier UUID:
Author:
Date: 2022-03-01T11:25:49.000+09:00
Remarks:

General information

Reference Type
study report

Title
In Vitro Chromosomal Aberration Test of 1,3-Propanediol, 2-butyl-2-ethyl on Cultured Chinese Hamster Cells.

Author
Ministry of Health, Labour and Welfare (MHLW), Japan

Year
2012

Bibliographic source
Japan Existing Chemical Data Base (JECDB) https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4f.pdf

Testing facility
Bozo Research Center Inc.

Report date
2012-03-23

Report number
T-G023

LITERATURE: Reverse Mutation Test of 1,3-Propanediol, 2-butyl-2-ethyl on Bacteria.

UUID:	58a6d996-8367-451e-9254-7f65dcd83b22
Dossier UUID:	
Author:	
Date:	2022-03-01T10:16:36.000+09:00
Remarks:	

General information

Reference Type
study report

Title
Reverse Mutation Test of 1,3-Propanediol, 2-butyl-2-ethyl on Bacteria.

Author
Ministry of Health, Labour and Welfare (MHLW), Japan

Year
2012

Bibliographic source
Japan Existing Chemical Data Base (JECDB) https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF115-84-4e.pdf

Testing facility
Bozo Research Center Inc.

Report date
2012-03-22

Report number
T-0879